Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Myasthenia gravis and Guillain-Barré syndrome adverse events with immune checkpoint inhibitors.
Authors
Catherine R. Garcia
University of Kentucky, Lexington, KY
Catherine R. Garcia, Jessica N Cox, John L. Villano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 37)
DOI
10.1200/JCO.2018.36.5_suppl.37
Abstract #
37
Poster Bd #
D5
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Early combination with mycophenolate mofetil for immune-related hepatitis in patients with solid tumors treated with immune checkpoint inhibitors.
First Author: Yukiko Shimoda Igawa
Poster
2023 ASCO Annual Meeting
Safety of checkpoint inhibitors in older patients with genitourinary cancers.
First Author: Brian Hemendra Ramnaraign
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2023 ASCO Genitourinary Cancers Symposium
Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).
First Author: Talal El Zarif